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Skeletal muscle function largely depend on intactenergy metabolism,stress response,and antioxidant defense mechanisms. Inthis
study, we tested the eﬀect of a combined supplementation of α-lipoic acid (LA) plus coenzyme Q10 (Q10) on PPARγ-coactivator α
(PGC1α) activity, expression of glutathione-related phase II enzymes and glutathione (GSH) levels in cultured C2C12 myotubes.
Supplementation of myotubes with 250μmol/L LA plus 100μmol/L Q10 signiﬁcantly increased nuclear levels of PGC1α,am a s t e r
switch of energy metabolism and mitochondrial biogenesis. The increase of nuclear PGC1α was accompanied by an increase in
PPARγ transactivation, a downstream target of PGC1α, and an increase in mitochondrial transcription factor A mRNA centrally
involved in mitochondrial replication and transcription. Furthermore, supplementation of myotubes with LA plus Q10 resulted
in an increase of genes encoding proteins involved in stress response, GSH synthesis, and its recycling. In LA-plus-Q10-treated
myotubes a signiﬁcant 4-fold increase in GSH was evident. This increase in GSH was accompanied by increased nuclear Nrf2
proteinlevels,partlyregulatingγGCSandGSTgeneexpression.Presentdatasuggestthatthecombinedsupplementationofskeletal
muscle cells with LA plus Q10 may improve energy homeostasis, stress response, and antioxidant defense mechanisms.
1.Introduction
The peroxisome proliferator-activated receptor γ (PPARγ)-
coactivator α (PGC1α) has been characterized as a master
switch of energy homeostasis [1]. PGC1α interacts with
transcription factors such as PPARγ, which is a downstream
target of PGC1α, thereby mediating adaptive thermogenesis,
mitochondrial biogenesis, and ﬁber type switching of the
skeletal muscle [1]. Gain-of-function studies indicate an
increased resistance to induced fatigue in isolated skeletal
muscle of transgenic mice overexpressing PGC1α [2]. An
activation of PGC1α is associated with an increased expres-
sion of slow-twitch (type I) ﬁbers which are characterized
by an increased mitochondrial biogenesis and thus oxidative
metabolism as main energy source [1]. Physical exercise
may activate PGC1α [3], whereas aging is accompanied by a
signiﬁcant decrease of PGC1α expression in skeletal muscle
[4]. This decrease in PGC1α may impair mitochondrial
respiratory capacity, thereby increasing the production of
reactive oxygen species which in turn results in glutathione
(GSH) depletion and oxidative stress. Thus, strategies are
warranted that activate PGC1α and increase GSH synthesis
and its recycling thereby maintaining muscle function and
integrity.
α-Lipoic acid (LA) is synthesized from octanoic acid
in the mitochondria where it serves as a cofactor of mito-
chondrial α-ketoacid dehydrogenase [5]. Beside endogenous
synthesis LA may also derive from exogenous dietary sources
including supplements (reviewed by [6]). As a component
of the electron transport chain in the inner mitochondria
membrane, coenzyme Q10 also known as ubiquinone is
centrally involved in cellular respiration and mitochondrial2 Oxidative Medicine and Cellular Longevity
biogenesis. Furthermore, it is well known for its free radical
scavenging properties, which are partly mediated by electron
transfer (reviewed by [7]). LA and Q10 may not work in
isolation [8] although little is known regarding the potential
synergistic activity of LA plus Q10 in terms of muscle cell
physiology. Therefore, in this study we investigated the eﬀect
of a combined supplementation of LA plus Q10 on PGC1α
levels, stress response, and glutathione synthesis in cultured
myotubes.
2.MaterialsandMethods
R(+)LA and Q10 were obtained from Sigma-Aldrich Co.
(Munich, Germany). LA was dissolved in DMSO (Carl Roth,
Karlsruhe, Germany). Q10 stock solutions were prepared as
described previously [9] .T h es t o c ks o l u t i o n sw e r es t o r e da t
−80◦C until usage.
2.1. Cell Culture. C2C12 cells (Institute for Applied Cell
Culture, Munich, Germany) were maintained in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) containing 4.5g/L glu-
cose, 4mmol/L L-glutamine, 1mmol/L sodium pyruvate,
10% fetal calf serum (FCS), 100U/mL penicillin, and
100μg/mLstreptomycin(PAA,Coelbe,Germany).Cellswere
grown in 5% CO2 at 37◦C under a humidiﬁed atmosphere.
Before each treatment, C2C12 cells were diﬀerentiated to
myotubes via serum starvation applying DMEM supple-
mented with 2% horse serum (Gibco, Life technologies,
Carlsbad, USA) for 48h–72h. All cell-culture plasticware
was purchased from Sarstedt (Numbrecht, Germany) unless
otherwise stated. For all cell culture assays vehicle controls
havebeenperformedanddidnotaﬀectanyoftheparameters
measured.
2.2. Cytotoxicity Measurement. Cytotoxicity was determined
via the neutral red assay [10]. The neutral red assay is based
on the pH-dependent accumulation of neutral red in the
lysosomes of viable cells. C2C12 cells were seeded in 24-well
plates (Fisher Scientiﬁc, Schwerte, Germany) at a density of
100,000 cells/well, diﬀerentiated for 72h, and treated with
250μmol/L LA plus 100μmol/L Q10 for 24h in serum-
containing medium, respectively. The culture medium con-
taining the test substances was replaced with fresh serum-
containing medium including 50μg/mL of neutral red (Carl
Roth). After incubation for 3h, the medium was removed
and the cells were extracted using a solution comprising
50:49:1 (v/v/v) ethanol, water, and glacial acetic acid. The
absorbance was measured in a plate reader (Labsystems,
Helsinki, Finland) at 540nm.
2.3. Transient Transfection and PPARγ Luciferase Reporter
GeneAssay. C2C12cellswerediﬀerentiatedin24-wellplates.
The cells were transiently transfected with three vectors: one
vector containing the PPARγ-LBD (ligand-binding domain),
one UAS-GAL4-vector containing the reporter gene ﬁreﬂy
luciferase, and a normalization vector (pRL-TK; Promega,
Mannheim, Germany) containing the Renilla reniformis
luciferase gene. Transfection was performed using JetPei
transfection reagent (Polyplus transfection, Illkirch Cedex,
France) according to manufacturer’s instructions. Following
24h of transfection the test compounds as well as 1μM
rosiglitazone were applied in serum-containing medium and
treated for 24h. Subsequently, cells were lysed and luciferase
activity was measured using the Dual-Luciferase reporter
geneassaysystem(Promega)accordingtothemanufacturer’s
protocol in a Tecan Inﬁnite 200 microplate reader (Tecan
Group Ltd., Crailsheim, Germany).
2.4. RNA Isolation and Real-Time PCR. C2C12 cells were
precultured in 6-well plates at a density of 300,000 cells/well.
Cells were diﬀerentiated and subsequently treated with
250μmol/L LA plus 100μmol/L Q10 and the respective
compounds in coapplication for 16h.
RNA for real-time PCR was isolated with TRIsure fol-
lowing the manufacturer’s protocol (Bioline, Luckenwalde,
Germany). Primers were designed by primer3 software with
the following sequences: PGC1α forward: TGCCCAGAT-
CTTCCTGAACT; reverse: TCTGTGAGAACCGCTAGCAA;
TFAM forward: TAGGAAAATTGCAGCCCTGT; reverse:
GCTGAACGAGGTCTTTTTGG; 18SrRNA forward: CCT-
GCGGCTTAATTTGACTC; reverse: AACTAAGAACGG-
CCATGCAC (MWG Biotech, Ebersberg, Germany). Real-
time PCR was performed using Sensi-Mix one-step kit
(Quantace, Berlin, Germany).
2.5.AgilentMicroarrayAnalysis. Diﬀerential geneexpression
was determined via an Agilent MicroArray platform (Source
BioScience, ImaGenes GmbH, Berlin, Germany). C2C12
cells were treated as described above. RNA for gene chip
analysiswasisolatedusingaQiagenRNeasyKit(Duesseldorf,
Germany) according to the manufacturer’s protocol. Agilent
Quick Amp Labeling Kit One Color (Agilent Technologies,
Santa Clara, USA) was used according to the manufacturer’s
instructions for generation and ampliﬁcation of ﬂuorescent
cRNA. Yield and labeling of cRNA was controlled via
NanoDrop measurement (Thermo Fisher Scientiﬁc). For
hybridization, the Agilent gene expression hybridization kit
was used according to the manufacturer’s protocol. The
microarray slides were washed (following the Agilent proto-
col) and subsequently scanned using an Agilent microarray
scanner. Data were extracted using the Agilent Feature
Extraction. Quality parameters (e.g., background detrend or
grid) and abnormalities of each sample were monitored.
For microarray analysis DAVID Bioinformatics Resour-
ces6.7(DatabaseforAnnotation,VisualizationanIntegrated
Discovery [11]; http://david.abcc.ncifcrf.gov/)w a su s e d .
Therefore, gene IDs of the regulated genes (fold change > 2
or< −2)wereuploaded.Forsubsequentfunctionalclustering,
KEGG (Kyoto Encyclopedia for Genes and Genomes) path-
w a ym a p sw e r eu s e d .
2.6. In Silico Promoter Analysis. F o rp r o m o t e ra n a l y s i s ,
sequences of genes diﬀerentially regulated by LA plus
Q10 treatment were uploaded to MatInspector Software
(http://www.genomatix.de/) in order to identify putative
binding sites for Nrf2.Oxidative Medicine and Cellular Longevity 3
2.7.GlutathioneMeasurement. C2C12cellsweretreatedwith
the test compounds for 24h as described above. Subse-
quently, cells were washed and lysed in 10mmol/L HCl and
repeated freeze-thaw cycles. GSH was determined following
the microtiter plate assay protocol according to Vandeputte
et al. [12]. In brief, cell protein was precipitated by addi-
tion of 6.5% sulfosalicylic acid and centrifugation (2000×
g, 15min). Cell samples were applied on the microtiter
plates, mixed with stock buﬀer and a reagent mix com-
prising (ﬁnal reaction concentration) 0.71mmol/L DTNB
and 0.24mmol/L NADPH. The reaction was initialized by
addition of glutathione reductase (1.2IU/mL, Sigma Aldrich
Co.). Kinetic measurement of the chromophore DTNB-GSH
at 415nm was performed in a plate reader (Labsystems,
Helsinki, Finland). Total glutathione was determined using a
GSH-standard curve (all reagents Carl Roth unless otherwise
stated).
2.8. Western Blot Analysis of PGC1α and Nrf2 in Nuclear
Extracts. For PGC1α and Nrf2 detection, cells were treated
with the test compounds for 6h. Subsequently, cells were
washed with ice-cold PBS, scraped oﬀ,c e n t r i f u g e d ,a n d
nuclear extracts were subsequently prepared as described by
Wagner et al. (2010) [13]. A quantity of 40μgp r o t e i no fe a c h
sample were mixed with loading buﬀer, incubated at 95◦C
for 5min and separated on a 12% SDS-PAGE. Subsequently,
the samples were transferred onto a PVDF (polyvinylidene
ﬂuoride) membrane and blocked with 3% (w/v) skim milk
dissolved in TBS + 0.05% (v/v) Tween-20 (TBST) for at least
2h and probed with antibodies against PGC1 (1:200; Santa
Cruz Biotechnology Inc., Santa Cruz, USA), Nrf2 (1:200;
Santa Cruz), TATA box binding protein (TBP; Santa Cruz;
1:200), or α-tubulin (Abcam, Cambridge, UK; 1:5000) at
4◦C overnight. Following, the membranes were incubated
with a secondary antibody (1:4000 anti-rabbit (Bio-Rad,
Munich, Germany): Nrf2; 1:4000 anti-mouse (Bio-Rad):
TBP, α-tubulin; 1:3000 anti-goat (Santa Cruz): PGC1) for
1h, and the bands were visualized by using ECL reagent
(Thermo Scientiﬁc) in a ChemiDoc XRS system (BioRad).
Molecular weight of the protein bands was estimated using a
Western C protein standard (Bio-Rad).
2.9. Statistical Analysis. Statistical analysis was conducted
using SPSS 19 (IBM, Chicago, USA). Data were analysed
for normality of distribution (Kolmogorov-Smirnov). In
case of not normally distributed data the nonparametric
Mann-Whitney U test was applied. Student’s t-test or
one-way analysis of variance (ANOVA) with a Dunnett-T
(homogeneous variances) post hoc test was performed. Data
a r ee x p r e s s e da sm e a n± SEM. Signiﬁcance was accepted at
P<0.05.
3. Results
In order to test for cytotoxicity of the test compounds
C2C12 myotubes were incubated with 250μmol/L LA plus
100μmol/L Q10 (in the following abbreviated as LA plus
Q10) for24h. Underthe conditions investigated cell viability
was not negatively aﬀected by the LA plus Q10 treatment
(Figure 1(a)).
PGC1α is an important regulator of skeletal muscle
energy homoeostasis. Therefore, we determined PGC1α
nuclear protein levels following 6h of incubation with LA
plus Q10. LA plus Q10 supplementation of C2C12 myotubes
signiﬁcantly enhanced nuclear PGC1α protein levels as
summarized in Figure 1(b).D i ﬀerences in PGC1α protein
levels in response to the LA plus Q10 treatment were also
reﬂected in terms of PGC1α gene expression (Figure 1(c)).
In fact we found a 70% increase in PGC1α mRNA levels
in LA-plus-Q10-treated myotubes as compared to untreated
control cells.
PGC1α is centrally involved in the regulation of PPARγ
a c t i v i t y ,w h i c hi sad o w n s t r e a mt a r g e to fP G C 1 α. There-
fore, we determined PPARγ transactivation in transiently
transfected C2C12 myotubes using a luciferase reporter
gene assay. Rosiglitazone (1μmol/L; rosi) was used as
positive control. Treatment of our C2C12 myotubes with
LA plus Q10 signiﬁcantly increased PPARγ transactivation
by approximately 50% (Figure 1(d)). However, LA plus Q10
cotreatment was less potent than rosiglitazone as far as the
induction of PPARγ transactivation is concerned.
Aerobic muscle turnover may be accompanied by induc-
tion of reactive oxygen species which are partly produced in
the respiratory chain of the inner mitochondrial membrane.
Therefore, we investigated if and to what extent the appli-
cation of LA plus Q10 may aﬀect cellular GSH which is an
important endogenous antioxidant. By using Agilent gene
chip technology we found several transcripts to be diﬀeren-
tially regulated by LA plus Q10 in our C2C12 myotubes. We
ﬁltered those genes in terms of their role in GSH synthesis,
metabolism, and recycling. Interestingly within the GSH
pathway 12 genes were diﬀerentially regulated (P value <
0.001, Benjamini enrichment score < 0.05) due to the LA
plus Q10 supplementation as summarized in Figures 2(a)
and 2(b).
Both γGCS light and heavy chain were manifold upreg-
ulated by the LA plus Q10 treatment. Since γGCS is the
key enzyme in GSH synthesis we further determined cellular
GSH levels in our skeletal muscle cells. Importantly, the
induction of γGCS gene expression was accompanied by a
4-fold increase in cellular GSH in the LA-plus-Q10-treated
cells as compared to control (Figure 2(c)).
Glutathione reductase (GSR) is centrally involved in
the NADPH-mediated reduction of GSSG to GSH, thereby
providing GSH for further reactions. Following incubation
with LA plus Q10, we observed a 3.2-fold increase in GSR
gene expression (Figure 2(c)). Interestingly, not only GSR
but also glucose-6-phosphate dehydrogenase 2 (G6PD) and
phosphogluconate dehydrogenase (PGD) gene expression
was induced by LA plus Q10. Both enzymes provide NADPH
which is used by GSR for GSSG reduction.
Induction of glutathione-S-transferase (GST) may pro-
tect the skeletal muscle from lipid peroxides thereby improv-
ing stress response. In fact, it has been shown that GST
inactivates lipid peroxides such as 4-hydroxynonenal due
to conjugation with GSH [14]. We found in our myotubes
various genes encoding GST (GST α1, GST α2, GST α3, GST4 Oxidative Medicine and Cellular Longevity
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Figure 1: (a) Viability of diﬀerentiated C2C12 cells following incubation with 250μmol/L LA plus 100μmol/L Q10 for 24h (data are
mean + SEM). (b) PGC1 induction in C2C12 cells following incubation with 250μmol/L LA plus 100μm o l / LQ 1 0f o r6hi nn u c l e a rc e l l
lysates and (c) PGC1α mRNA levels in response to the LA plus Q10 treatment (data are mean + SEM of three independent experiments;
∗indicates signiﬁcant diﬀerence to the control cells; P<0.05; Student’s t-test). (d) The increase in PGC1α is accompanied by an increased
PPARγ transactivation as shown in transiently transfected C2C12 cells (data are mean + SEM of two independent experiments; ∗indicates
signiﬁcant diﬀerence to the control cells; P<0.05; one-way ANOVA).
α4, GST π1, GST π2, GST μ6) to be upregulated by the
cotreatment of LA plus Q10 (Figures 2(a) and 2(b)).
To identify binding sites for Nrf2 in murine promoter
regions in LA-plus-Q10-regulated genes, the respective
murine promoter sequences were uploaded to MatInspector.
As summarized in Figure 2(b), several binding sites for Nrf2
have been identiﬁed in the promoter of the γGCS (GCLC
(0–4 putative binding sites), GCLM (0–4)), GSR (1–5), GST
(GSTα1(1-2),GSTα2(1),GSTα3(0–2),GSTα4(0/4),GST
π1(0–8),GSTπ2(0–8),GSTμ6(0–2))ODC1(1),G6PD(1),
and PGD (1–6) genes, respectively, (Figure 2(b)).
Treatment of C2C12 cells with LA plus Q10 increased
TFAM mRNA levels by 70% (P = 0.078) as compared to
controls (Figure 3(a)). Furthermore, LA plus Q10 supple-
mentation resulted in an increase in nuclear Nrf2 levels as
summarized in Figure 3(b).
4. Discussion
Under the conditions investigated LA plus Q10 signiﬁcantly
increased nuclear PGC1α levels in our C2C12 skeletal muscle
cells. PGC1α partly controls PPARγ activation which isOxidative Medicine and Cellular Longevity 5
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determined via MatInspector. (c) Glutathione (GSH) concentration in C2C12 cells in response to LA plus Q10 treatment (data are mean +
SEM of three independent experiments; ∗indicates signiﬁcant diﬀerence to the control cells; P<0.05; Student’s t-test).
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Figure 3: (a) TFAM mRNA and (b) nucleic Nrf2 protein levels of C2C12 cells following incubation with 250μmol/L LA plus 100μmol/L
Q10 for 16h (mRNA data are mean + SEM of three independent experiments; Mann-Whitney U test).
centrally involved in cellular glucose uptake. In fact it has
been previouslyshown thatlipoic acidmay stimulate glucose
uptake and insulin sensitivity in adipocytes via a PPARγ-
dependent signal transduction pathway [15, 16].
PGC1α is a key factor in mitochondrial biogenesis.
PGC1α, in the presence of the nuclear respiratory factor 1
(NRF1), coactivates the mitochondrial transcription factor
A (TFAM; also called mtTFA) which is essential for mito-
chondrial replication and transcription [17, 18]. Therefore,
we determined TFAM levels in our LA-plus-Q10-treated
myotubes. Interestingly, LA plus Q10 resulted in an increase
in TFAM mRNA levels as compared to untreated controls
(Figure 3(a)). LA plus Q10 cotreatment was more potent
than the single treatment with LA and Q10 per se in
increasing TFAM gene expression (data not shown). Further
studies are needed to prove whether the increase in TFAM
gene expression due to the LA plus Q10 cotreatment is also
reﬂected in terms of increased nuclear TFAM protein levels
as well as an increased cellular mitochondrial density, ATP
synthesis, and oxygen consumption.Oxidative Medicine and Cellular Longevity 7
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encoding enzymes involved in GSH synthesis and recycling. Ultimately, LA plus Q10 may increase mitochondrial biogenesis, improve stress
response, and increase cellular GSH levels.
We observed a signiﬁcant increase in cellular GSH levels
in response to LA plus Q10 treatment in our skeletal muscle
cells. Similar to PGC1α cellular GSH levels decrease with
age [19] .T h u s ,L Ap l u sQ 1 0m a yp r e v e n ta g e - d e p e n d e n t
GSH depletion. The underlying mechanisms by which LA
plus Q10 increased cellular GSH may be partly related to
an increased cysteine uptake as previously reported [20].
Furthermore, in the present study LA plus Q10 signiﬁcantly
increased gene expression of γGCS, the rate limiting enzyme
of GSH synthesis. γGCS gene expression is under transcrip-
tionalcontrolofnuclearfactorerythroid-like2derivedfactor
2 (Nrf2), a Cap N’Collar basic leucine zipper transcription
factor [21–23]. Interestingly, LA plus Q10 treatment also
manifold upregulated numerous GSTs which are also Nrf2
target genes [24]. Therefore, we determined Nrf2 nuclear
levels in our skeletal muscle cells in response to the LA plus
Q10 treatment. Since LA plus Q10 treatment substantially
increased nuclear Nrf2 levels, it seems plausible that the
induction of GSH via γG C Sa sw e l la st h ei n d u c t i o no fG S T
gene expression in our C2C12 cells may have occurred via
a Nrf2-dependent mechanism. In fact, it has been recently
suggested that LA, may act as an electrophile which targets
cysteine residues of the Nrf2 inhibitor Keap1 [25].
Ourgeneexpressionanalysisalsorevealsornithinedecar-
boxylase 1 (ODC1) as a LA plus Q10 sensitive molecular
target (fold change = 2.1, see Figure 2(b)). Interestingly,
ODC1 is induced by exercise in skeletal muscle [26]. The
increase in ODC1 activity may in turn increase cellular
levels of putrescine, spermine, and spermidine [27], thereby
improving DNA stability [28], which warrants further
investigations.
In this study we tested the combination of LA plus Q10
in terms of PGC1α activity, stress response, and cellular GSH
levels. However, we conducted also experiments using LA
and Q10 as single treatments in order to relate our results
to any of the test substances administered (data not shown).
While Q10 was mainly mediating PGC1α inducing activity,
LA increased stress response and cellular GSH levels. As far
as TFAM gene expression is concerned, neither of the single
test compounds enhanced TFAM. Thus, TFAM induction
may be due to synergistic interaction between LA and Q10
in coapplication. Accordingly, in order to simultaneously
induce PGC1, stress response genes, and cellular GSH levels
in skeletal muscle cells a combination of LA plus Q10
rather than a treatment with the single compound may be
suggested.
Overall present data indicate that a combination of lipoic
acid plus coenzyme Q10 induces PGC1α,i m p r o v e ss t r e s s
response, and increases cellular glutathione levels in cultured
C2C12 skeletal muscle cells as summarized in Figure 4.8 Oxidative Medicine and Cellular Longevity
We supplemented our myotubes with 250μmol/L LA and
100μmol/L Q10. LA concentrations, as used in this study,
are by in large physiologically achievable [6, 29], whereas
Q10 levels seem to be higher than those achievable in human
plasma and skeletal muscle [30]. Thus, current ﬁnding
regarding the role of LA and Q10 in terms of PGC1α activity,
stress response, and antioxidant defense in cultured skeletal
muscle cells in vitro should be veriﬁed in appropriate in vivo
models.
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